Cart 0 $0.00
IRE favicon

Shop

Resource ID: #26852
Subject: Drugs
Source: PBSNewshour
Affiliation: 
Date: 2014-06-28

$0.00

Description

Are generic drugs delayed to market by so-called “pay-for-delay” deals between brand and generic drug manufacturers? PBS NewsHour Weekend investigated these deals and other practices that opponents like the Federal Trade Commission say are meant to impede generic competition and protect profits. PBS NewsHour Weekend profiled Karen Winkler, a 46-year-old mother of three with Multiple Sclerosis. A deal was struck over her M.S. drug that opponents say delayed the generic to market. Then, the manufacturer raised the price to get patients to switch to its new extended-release version. Unable to afford it, Karen went off the drug until it went generic in 2012. PBS NewsHour Weekend shed light on complicated, secretive pharmaceutical deals rarely examined on national TV. These deals affect thousands of patients, but few know anything about them. And in cases like Winkler's, they can have profound consequences.

109 Lee Hills Hall, Missouri School of Journalism   |   221 S. Eighth St., Columbia, MO 65201   |   573-882-2042   |   info@ire.org   |   Privacy Policy
apartmentpenciluserscalendar-fullcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram
My cart
Your cart is empty.

Looks like you haven't made a choice yet.